Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity [3]

Leukemia

Volumn 20, Issue 5, 2006, Pages 881-883

  Mathews, V ^a   Desire, S ^a   George, B ^a   Lakshmi, K M ^a   Rao, J G ^a   Viswabandya, A ^a   Bajel, A ^a   Srivastava, V M ^a   Srivastava, A ^a   Chandy, M ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTHRACYCLINE DERIVATIVE; ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; DAUNORUBICIN; HYDROXYUREA; LIVER ENZYME; MITOXANTRONE; RETINOIC ACID;

BRAIN HEMORRHAGE; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TRANSFORMATION; ENZYME DEFECT; GENETIC POLYMORPHISM; HEART DISEASE; HEPATOMEGALY; HUMAN; INCIDENCE; LETTER; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SEPSIS; SUDDEN DEATH; TREATMENT OUTCOME;

EID: 33646145533     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404165     Document Type: Letter

References (9)

1. Douer D, Tallman MS. Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005; 23: 2396-2410.
2. Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett 2000; 112-113: 209-217.
3. Brouwer OF, Onkenhout W, Edelbroek PM, de Kom JF, de Wolff FA, Peters AC. Increased neurotoxicity of arsenic in MTHFR deficiency. Clin Neurol Neurosurg 1992; 94: 307-310.
4. Chiou HY, Hsueh YM, Hsieh LL, Hsu LI, Hsu YH, Hsieh FI et al. Arsenic methylation capacity, body retention and null genotypes of glutathione S-transferases M1 and T1 among current arsenic exposed residents of Taiwan. Mutat Res 1997; 386: 197-207.
5. Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001; 11: 663-669.
6. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999; 96: 12810-12815.
7. Arand M, Muhlbauer R, Hengstler J, Jager E, Fuchs J, Winkler L et al. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 1996; 236: 184-186.
8. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramaniam P et al. Single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 2005, Dec 13 (E-pub ahead of print).
9. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell Jr RP. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296.